Pei Hui, PhD, MD
Cards
About
Titles
Professor of Pathology and of Obstetrics, Gynecology and Reproductive Sciences
Director, Gynecologic Pathology; Clinical Director, Molecular Diagnostics Laboratories; Director, PathologyBiography
Dr. Hui is Professor in the Department of Pathology and Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine. Dr. Hui obtained his medical degree from Xi’an Jiaotong University in China in 1984. He received combined anatomic and clinical pathology residency training at Yale-New Haven Hospital in 2000, followed by oncological pathology fellowship training at MSKCC in 2001. Dr. Hui is a board-certified surgical pathologist with clinical expertise in gynecologic pathology and diagnostic molecular pathology. He is Director of Gynecologic Pathology, Clinical Director of Molecular Diagnostics Laboratory, and Director of Center for the Precision Medicine of Trophoblastic Disease at Yale School of Medicine. He has authored over 280 publications including four gynecological pathology textbooks. Dr. Hui serves on the editorial boards of International Journal of Gynecological Pathology, Modern Pathology, Human Pathology and Virchows Archiv. Dr. Hui is a consensus/expert editorial board member of the 4th (2014) and 5th (2020) editions of WHO Tumor Classifications of Female Reproductive Organs. Dr. Hui serves on the Board of Directors of the International Society of Gynecological Pathologists (ISGyP) and is President-Elect of the society.
Appointments
Pathology
ProfessorPrimaryObstetrics, Gynecology & Reproductive Sciences
ProfessorSecondary
Other Departments & Organizations
- Center for Precision Diagnosis of Trophoblastic Disease
- Gynecologic Oncology Program
- Gynecological Pathology
- Gynecological Pathology
- Molecular & Genomic Pathology
- Obstetrics, Gynecology & Reproductive Sciences
- Pathology
- Pathology and Molecular Medicine
- Pathology Research
- Surgical Pathology
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
Education & Training
- Fellowship
- Memorial Sloan Kettering Cancer Center (2001)
- Residency
- Yale School of Medicine (2000)
- PhD
- SUNY at Buffalo (1994)
- MS
- Peking University, Tumor Biology (1987)
- MD
- Xian Medical University (1984)
Research
Academic Achievements and Community Involvement
Clinical Care
Overview
Pei Hui, MD, PhD, is a pathologist who specializes in gynecological diseases and cancers, including endometrial, ovarian, and fallopian tube cancers.
“You understand disease better through pathology,” Dr. Hui says. “You learn how it develops and its mechanisms at a cellular and molecular level.”
Dr. Hui points out that although pathologists rarely see patients face-to-face, they are still in charge of the well-being of the patient through the microscopic diagnosis. “We look at 30 to 50 cases each day, so in a way you could say that we see more patients than any other physician,” he says.
Dr. Hui says that he enjoys working as a team to provide better care for patients. For example, on any given day, he might be talking via phone, email, or text, to a patient’s oncologist or doctor. “We are informative for them because we provide timely and accurate diagnosis and using new biomarkers that may change the patient treatment options. The boundary between physician and pathologist is smaller than ever.”
What most excites Dr. Hui is the ability to improve diagnostic accuracy and find new biomarkers to guide clinical management for patients and prognosis. He continues his research in that area as professor and director of gynecologic pathology at Yale School of Medicine.
Clinical Specialties
Board Certifications
Molecular Genetic Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2003
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2000
Links & Media
Media
Pathogenesis of Hydatidiform Moles
Acquisition of global imprinting alteration at a critical time point in a preimplantation embryo occurs through the de novo absence of the maternal haploid genome in sporadic androgenetic complete hydatidiform moles (CHMs) or through mutations of NLRP7 or KHDC3L shutting down the entire maternal imprinting gene expression in familial biparental CHMs (from Annu. Rev. Pathol. Mech. Dis. 2017. 12:449–85).Atypical Placental Site Nodule
Atypical placental site nodule (APSN). As a precursor lesion to epithelioid trophoblastic tumor, APSN has morphologic features, including larger size of greater than 5 mm (A), increased cellularity (B and C), marked nuclear atypia (C and D), increased mitotic activity (D, arrows), and increased Ki-67 proliferation index to 8%to 10% (E and F) (hematoxylin-eosin, original magnifications320 [A],3100 [B and E], and3400 [C and D]; Ki-67, original magnification3100 [F] (from Arch Pathol Lab Med. 2018 Nov 8; 2018 Nov 8. PMID: 30407075)Minimal Microsatellite Shift in Endometrial Cancer
Microsatellite instability testing by analysis of PCR products amplified at 5 NCI recommended loci. a: Minimal microsatellite shift at four of 5 microsatellite loci (red arrows) in an endometrial endometrioid adenocarcinoma. b: Major microsatellite shifts (blue arrows) and minimal microsatellite shifts (red arrow) in a colorectal carcinoma). (From Mod Pathol. 2018 Nov 15; 2018 Nov 15. PMID: 30443012)DNA Mismatch Repair Mechanism
DNA mismatch repair mechanism. MLH1 dimerizes with PMS2, PMS1 or MLH3 to form MutLα, MutLβ or MutLγ heterodimer, respectively. MSH2 dimerizes with MSH6 or MSH3 to form MutSα or MutSβ heterodimer respectively, with the main function of binding DNA helix and recognizing DNA mismatches. Working together with the MutL complexes, the MSH2/MSH6 (MutSα) complex guides the repair of single base mismatch and small loop mismatch, whereas the MSH2/MSH3 (MutSβ) complex guides the repair of small to large loop mismatch (Expert Review Of Molecular Diagnostics 2016, 16:591-604. 2016).
News
- July 01, 2024
Pei Hui, MD, PhD, Chosen as President-Elect of International Society of Gynecological Pathologists
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 09, 2024
Topical Shows Promise in Treating Precancerous Cervical Condition
- November 07, 2023
Yale Diagnostic Pathology Annual CME Review held in NYC